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Background: Scaffold-assisted autologous chondrocyte implantation is an effective clinical procedure for cartilage
repair. From the regulatory point of view, the ovine model is one of the suggested large animal models for
pre-clinical studies. The aim of our study was to evaluate the in vitro re-differentiation capacity of expanded ovine
chondrocytes in biomechanically characterized polyglycolic acid (PGA)/fibrin biomaterials for scaffold-assisted
cartilage repair.
Methods: Ovine chondrocytes harvested from adult articular cartilage were expanded in monolayer and
re-assembled three-dimensionally in PGA-fibrin scaffolds. De- and re-differentiation of ovine chondrocytes in
PGA-fibrin scaffolds was assessed by histological and immuno-histochemical staining as well as by real-time gene
expression analysis of typical cartilage marker molecules and the matrix-remodelling enzymes matrix
metalloproteinases (MMP) -1, -2 and −13 as well as their inhibitors. PGA scaffolds characteristics including
degradation and stiffness were analysed by electron microscopy and biomechanical testing.
Results: Histological, immuno-histochemical and gene expression analysis showed that dedifferentiated
chondrocytes re-differentiate in PGA-fibrin scaffolds and form a cartilaginous matrix. Re-differentiation was
accompanied by the induction of type II collagen and aggrecan, while MMP expression decreased in prolonged
tissue culture. Electron microscopy and biomechanical tests revealed that the non-woven PGA scaffold shows a
textile structure with high tensile strength of 3.6 N/mm2 and a stiffness of up to 0.44 N/mm2, when combined with
gel-like fibrin.
Conclusion: These data suggest that PGA-fibrin is suited as a mechanically stable support structure for
scaffold-assisted chondrocyte grafts, initiating chondrogenic re-differentiation of expanded chondrocytes.
Keywords: Cartilage grafts, Chondrocytes, In vitro model, Scaffolds, Fibrin, Polyglycolic acid, Tissue engineering,
Regenerative medicine, Differentiation, BiomechanicsBackground
Articular cartilage has a limited intrinsic potential for re-
generation and repair. Traumatic or focal degenerative
defects are often associated with pain, loss of mobility,
stiffness and considerable limitations in quality of life
and may lead to severe osteoarthritis (OA) and total
knee replacement. Since cartilage defects occur fre-
quently, they represent a major and challenging health
problem. In knee arthroscopies up to 63% of the patients
with knee related symptoms show chondral or deeper* Correspondence: christian.kaps@transtissue.com
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reproduction in any medium, provided the orosteochondral defects, comprised of approximately 70%
focal non-degenerative defects and 30% osteoarthritic
defects [1-3]. It is suggested that eleven percent of all
knee arthroscopies show cartilage defects suitable for
cartilage repair procedures [4].
Clinically applied cartilage repair procedures comprise
debridement, bone marrow stimulating techniques like
drilling or microfracturing, osteochondral autograft
transfer and autologous chondrocyte implantation (ACI)
[5-9]. In ACI, a small cartilage biopsy is harvested from
the less weight-bearing area of the articular cartilage.
After isolation of the chondrocytes by enzymatic diges-
tion of the cartilage extracellular matrix, the cells areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chondrocyte implantation, the cartilage defect is deb-
rided down to the subchondral bone and a periosteal
flap or a collagen sheet is sutured onto the healthy car-
tilage. Thus, a self-contained compartment is created
that is subsequently filled with the chondrocyte cell sus-
pension by injection. In recent years, a variety of clinical
studies documented the clinical efficacy of in vitro
expanded chondrocytes for cartilage repair [10-13].
However, there is no significant evidence that the ACI
procedure is superior to other cartilage repair techniques
in the treatment of full-thickness articular cartilage
defects [8,14]. Nevertheless, ACI is regarded as a second
line treatment for small and a first line treatment for
defects larger than 2 to 4 cm2 [15].
The inherent technical disadvantages of ACI, such as
the need for an intact cartilage rim surrounding the defect,
the loss of chondrocytes into the joint space, loosening or
ablation of the periosteal flap, and periosteal hypertrophy,
may result in re-operations that are reported in up to
25%-36% of the cases [16,17]. Therefore, in recent years,
matrix- or scaffold-assisted cartilage tissue engineering
grafts were developed that use resorbable, three-
dimensional scaffolds and the known regenerative poten-
tial of autologous chondrocytes. For hyaluronan-based
[18,19], collagen-based [20,21], and resorbable polymer-
based [22] autologous chondrocyte grafts, clinical effect-
iveness for the repair of cartilage defects has been shown
for follow-up periods of two to five years.
The regulatory pathways for the approval of such cell-
based products, as set by the US Food and Drug Admin-
istration, FDA [23] or the European Medicines Agency
(EMA) have implications in the development of autolo-
gous chondrocyte grafts for orthopedic surgery. The
EMA guideline on human cell-based medicinal products
summarizes the issues to be addressed during the pre-
clinical development of cell-based, hence chondrocyte-
based grafts [24]. Pre-clinical studies should address
both proof-of-principle and the definition of pharmaco-
logical and toxicological effects predictive of the human
response, including e.g. quality parameters of the cell-
based product, dose-finding, route of administration, ap-
plication schedule and adverse effects. From the quality
point of view, characterization of the cellular as well as
the scaffold component of the graft is of special import-
ance and requires the definition of markers for cell iden-
tity, purity, impurities and for cell potency as well as
biomechanical testing of structural components like
matrices or scaffolds. These pre-clinical studies should
be performed in relevant animal models. Since different
large animal models bear inherent drawbacks with re-
spect to the prospected outcome and the particular cell-
based product, the choice of the animal model should be
underlined by a multi-factorial analysis [25]. In terms ofmarketing approval, the currently best available large
animal models for chondrocyte-based products are goat,
horse or sheep [26].
The aim of our present study was to evaluate the
in vitro differentiation behavior of culture expanded
adult ovine chondrocytes in resorbable scaffolds-assisted
cartilage grafts. Here we report that the cartilage
markers type II collagen and aggrecan are relevant
markers for cell identity and potency in the ovine model.
Re-differentiation of dedifferentiated ovine chondrocytes
in three-dimensional scaffolds-assisted cartilage grafts
in vitro as well as the biomechanical characteristics
of the scaffold suggests that chondrocytes embedded in
polyglycolic acid-fibrin scaffolds are well suited for cell-
based, scaffold-assisted cartilage repair.
Methods
Isolation and culture of ovine chondrocytes
Articular cartilage from six adult sheep (3–5 years, merino
mix) without macroscopic signs of osteoarthritis or other
cartilage injuries was used for the study. For cell culture
expansion, cartilage was harvested from the femoral and
tibial condyle under sterile conditions. Each donor tissue
was strictly handled separately. The cartilage was minced
and digested for 16h in RPMI 1640 medium (Biochrom)
containing 10% fetal bovine serum (FBS, Biochrom),
1.5 U/ml collagenase P (Roche), 500 U/ml collagenase
CLS type II (Biochrom), 50 U/ml hyaluronidase (Sigma),
100 μg/ml gentamycin (Biochrom), 100 U/ml penicillin
(Biochrom), 100 mg/ml streptomycin (Biochrom), and
250 μg/ml amphotericin B (Sigma). Viable cells as assessed
by trypan blue dye exclusion were seeded into cell cul-
ture flasks with an initial density of 2x105 cells/cm2 in
RPMI 1640 supplemented with 10% FBS and penicillin/
streptomycin. Medium was changed every 2 to 3 days.
After reaching 80% confluence the cells were detached
with trypsin/EDTA (Biochrom) and re-plated with a seed-
ing density of 2x105 cells/cm2.
Three dimensional assembly of scaffold-assisted cartilage
grafts
After 3 and 5 passages, the cells were detached and re-
suspended in Fibrinogen (Tissucol, Baxter) with a cell
density of 2.4*107 cells/ml. The cell/fibrinogen suspen-
sion was combined with 10 mm x 10 mm x 1.1 mm
PGA (polyglycolic acid) scaffolds (provided by BioTissue
Technologies GmbH, Freiburg, Germany). After adding
a thrombin solution (1:10 v/v PBS; Tissucol; Baxter),
polymerisation of fibrinogen was performed at 37°C for
20 min. The grafts (n = 12 per donor, n = 36 in total)
were cultured for up to 3 weeks in vitro in RPMI 1640
medium (Biochrom) supplemented with 5% FBS, 100 U/ml
penicillin (Biochrom), 100 mg/ml streptomycin (Biochrom)
and 50 μg/ml ascorbic acid (Sigma).
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Tissue and cell cultures derived from three independent
donors were homogenized in 1 ml TriReagent (Sigma,
Germany). Bromochloropropane was added, incubated
at room temperature for 10 minutes and centrifuged at
12.000 g for 15 minutes. The supernatants were used for
the isolation of total RNA using the Qiagen Rneasy Mini
Kit (Qiagen, Germany) according to the manufacturer’s
protocol. RNA was isolated from native cartilage, cul-
tured cells at passage 0, passage 3 and passage 5 as well
as after cartilage graft tissue culture for 1 weeks, 2 weeks
and 3 weeks (n = 3 each, per point in time). Subse-
quently, total RNA (3 μg) was reversely transcribed with
the iScript cDNA Synthesis Kit according to the manu-
facturer’s instructions (BioRad). Samples were normal-
ized according to the relative expression level of the
housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). Real-time PCR (i-Cycler PCR System,
BioRad) was performed using 1 μl of cDNA sample and
the SYBR Green PCR Core Kit (Applied Biosystems) in
triplicates. Relative quantitation of marker gene expres-
sion (Table 1) was performed and is given as percentage
of the GAPDH product.
Histology and immuno-histochemistry
For histological and immuno-histochemical analyses, car-
tilage grafts (n = 3 per donor and per point in time) were
embedded in OCT compound, frozen and cryo-sections
(10 μm) were prepared. For overall histological evaluation,
conventional hematoxylin & eosin staining was used. Pro-
teoglycans were visualized by staining with Alcian Blue
8GS (Roth) at pH 2.5. Nuclei were counterstained with
Nuclear Fast Red. Mineralization of the extracellular
matrix was visualized by von Kossa staining, followed by
counterstaining with eosin. Sections (n = 3) were incu-
bated in the dark at room temperature with 5% silver ni-
trate for 30 minutes following incubation with 1.7MTable 1 Oligonucleotides
gene name reference sequence oligonucleotides (5‘→3‘)
GAPDH AF02943 TGG AGT CCA CTG GGG TC
aggrecan AF019758 TCG GGG TAG GTG GCG A
type ΙΙα1 collagen AF138883 GCT GGT CAG AGG GGC A
MMP1 AF267156 CAT TCT ACT GAC ATT GG
MMP2 NM_001166180 CTT CCA GGG CAC ATC TT
MMP13 AF267157 TGC ATC CTC AGC AGG TT
osteocalcin NM_001040009 AGG GCA GCG AGG TGG T
TIMP1 NM_001009319 ACA GGT CCC AGA ATC G
TIMP2 NM_001166186 GGG CCA AAG CGG TCA G
TIMP3 NM_001166187 CCA CAC GGA AGC CTC TG
GAPDH glyceraldehyde-3-phosphate dehydrogenase.
MMP matrix metalloproteinase.
TIMP tissue inhibitor of metalloproteinases.sodium carbonate/10% (v/v) formalin for 5 minutes. After
washing with tap water for 10 minutes, counterstaining
was performed with nuclear fast red for 4 minutes. For
immuno-histochemical analysis of type II collagens, cryo-
sections were incubated for 40 minutes with the primary
antibody (rabbit anti-human type II collagen, Acris). Sub-
sequently, sections were processed using the EnVision
System Peroxidase Kit (DAKO) according to the manufac-
turer’s recommendations, followed by counterstaining
with hematoxylin (Merck). To verify the presence of type
II collagen during expansion culture in monolayer, chon-
drocytes were seeded on cover slips (Permanox) at a dens-
ity of 1x 104 cells/cm2 directly after cell isolation (passage
0) and at passage 1, 3 and 5. Cells were fixed with acet-
one/methanol (1:1 v/v) and stained as described above.
For analysis of cell viability and homogenous cell distribu-
tion in 3D cartilage grafts, propidium iodide/fluorescein
diacetate (PI/FDA) staining (Sigma) was used. Grafts
(n = 3 per point in time) were rinsed with PBS, incubated
for 15 min at 37°C with 2 μg/ml FDA solution, rinsed
again with PBS and incubated with 0.1 mg/ml PI solution
for 2 min at room temperature. Grafts were analysed using
a fluorescence microscope (Olympus AX70).
Biomechanics
For testing the mechanical strength and degradation of
the scaffold, uniaxial tensile tests were performed using a
Zwick material testing machine (Zwick, Ulm, Germany).
The maximum failure load and tensile strength of the
scaffolds (60 mm x 5 mm x 1 mm) was measured under
standardized conditions by using a clamp distance of
20 mm and a crosshead speed of 100 mm/min. To
characterize the mechanical strength, the ultimate tensile
load until failure/rupture of the scaffold was measured.
For degradation, the scaffolds were stored in phosphate-
buffered saline (Biochrom) at 37°C for up to 10 days.
Failure load was measured at day 0 (n = 30, without(up/down) product size
(base pairs)
T TCA CTA/TTG CTG ACA ATC TTG AGG GTA TT 160
GG AA/GGG CGG TTG GGG AGA CTT CAA 150
TC GTT/AGG GGG ACC TCG GTC TCC AGA T 129
G GCT CTG/GAA TCG TAG TTA TGG CAT CAA AAG T 190
A CGA CAG/ACA TGG GGC ACC TTC CGA GTT 160
G AAG C/GTC ATG GGA AGG GTG CTC ATA GG 101
GA AG/GCC GTA GAA GCG CCG ATA GG 173
CA GTG AG/CAG CAG CAT AGG TCT TGG TGA ATC C 147
TA AGA AG/AGA GGA GGG GGC TGT GTA GAT AAA C 149
A AAG TC/AGG GTA GCC GAA ATT GGA GAG CA 280
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10 days (n = 30 each).
For measuring the stiffness of scaffolds (diameter 8 mm,
thickness 1 mm), compression tests were performed as
described previously [27]. In brief, human articular cartil-
age (n = 2; diameter 18 mm, thickness 2 mm), PGA scaf-
folds (n = 6) and fibrin-PGA scaffolds (PGA scaffolds
immersed with fibrinogen and polymerized by the
addition of thrombin, see ‘Three dimensional assembly of
scaffold-assisted cartilage grafts‘; n = 6) were tested on a
MTS material testing machine. During an applied
displacement-time history, the compression of the speci-
men and the resulting force are measured. The compres-
sion tests were carried out in three stages. The test
specimens were firstly compressed up to a global strain of
1/3 of the specimen thickness with a displacement velocity
of 0.5 mm/s in the loading process, which was followed by
the constant compression stage for 20 seconds and the
unloading process with the same displacement velocity as
in the first stage. All tests were conducted as unconfined
compression tests. In order to avoid slipping of spe-
cimens perpendicular to the loading axis, rough paper
was placed between scaffold and support. The cartilage
samples exhibit cragged bone surfaces. For this reason,
these specimens were glued on resin to obtain a plane
lower surface. Deformations of the resin itself could
be neglected in comparison to the compression of the spe-
cimens. In order to determine and to compare the struc-
tural stiffness of specimens, a global stiffness by means of
the stress–strain relation was determined. The global
strain was obtained by relation between the specimens’
thickness and its compression. By curve fitting with a lin-
ear function of the stress–strain relation during the load-
ing stage in the regime of the compression peak, the
inclination of the stress–strain curve, representing a stiff-
ness, could be determined. It should be emphasized that
this value is not equal to the Young’s modulus of the
material due to the three-dimensional stress state. The
determined global stiffness is a measurement for the entire
sample structure providing information about its mechan-
ical properties.Scanning electron microscopy (SEM)
Scaffolds were fixed in 5% glutardialdehyde for two
hours at room temperature. The scaffolds were then
dehydrated for 30 minutes each in an ethanol series
from 50% up to 100% ethanol. Subsequently, scaffolds
were incubated for 12 hours in 100% ethanol. The etha-
nol was removed in a critical point dryer. For sputter
coating, the dried scaffolds were mounted on a stub and
coated with gold-palladium. The sputtered scaffolds
were evaluated in the scanning electron microscope
(Zeiss DSM 950) under a high vacuum mode.Statistical analysis
The Kolmogorov-Smirnov method was applied for test-
ing normal distribution of the data. For statistical ana-
lysis of the maximum failure load, normal distributed
data were further analyzed with the one way repeated
measures (RM) analysis of variance (ANOVA) and data
not showing a normal distribution with RM ANOVA on
ranks. Subsequently, the parametric paired t-test or the
non-parametric Wilcoxon signed rank test was applied.
Differences were considered significant at p < 0.05. For
statistical evaluation of differentially expressed genes,
the parametric paired t-test or the non-parametric
Wilcoxon signed rank test was applied. Differences were
considered significant at p < 0.05.
Results
Ovine articular cartilage and dedifferentiation of ovine
chondrocytes in vitro
Histological staining of ovine articular cartilage (Figure 1)
showed irregular distribution of chondrocytes with a
characteristic round-shaped morphology. The cells were
present as single cells or grow in isogenic groups of two
to three cells. The pericellular matrix was smooth and
regular (Figure 1A). The chondrocytes were surrounded
by cartilage matrix rich in proteoglycan showing a more
intense staining adjacent to the lacunae (Figure 1B).
Type II collagen that is characteristic for hyaline cartil-
age is evident and shows a regular and homogeneous
distribution within the extracellular matrix (Figure 1C).
Controls were negative and show specificity of the type
II collagen staining (Figure 1D).
For the preparation of cartilage grafts, chondrocytes
were harvested by enzymatic digestion of the cartilage
matrix and expanded using conventional cell culture
conditions (Figure 2). Within a few days, the cells
attached to the plastic surface of the cell culture plate.
At passage 0, more than 90% of the chondrocytes
showed an intense staining of type II collagen
(Figure 2A). The cells stretched, developed the shape of
elongated, fibrobast-like cells, and progressively lost type
II collagen during extensive expansion, at passage 1, 3
and 5 (Figure 2B – 2D).
Polyglycolic acid-fibrin scaffolds for chondrocyte-based
cartilage grafts
Expanded chondrocytes were embedded in fibrin and in
resorbable polyglycolic acid scaffolds that ensure initial
mechanical stability of the grafts (Figure 3). Scanning elec-
tronic microscopy of the PGA scaffold showed a non-
woven textile, felt-like structure with regular and smooth
PGA fibers (Figure 3A). The fibers were randomly
arranged in bundles or singular. The diameter of the fibers
was approximately 17μm (Figure 3B). To assess mechan-
ical strength and degradation properties of the scaffolds,
Figure 1 Histological analysis of typical cartilage extracelluar matrix components in native ovine articular cartilage. Hematoxylin & eosin
(A) staining shows that chondrocytes of the articular cartilage are irregularly distributed, with insular cells and cells in groups of two to three
chondrocytes. Alcian blue (B) staining shows the presence of proteoglycans and an intense staining surrounding the chondrocytes. Type II
collagen (C) immune-staining is homogenous and shows presence of the cartilage marker molecule in the pericellular extracellular matrix.
Controls (D), incubated with IgG were negative and show specificity of the type II collagen immune-staining.
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storage of the scaffolds in aqueous solution at body
temperature for up to 10 days (Figure 3C). At day 0, the me-
dian tensile strength of the PGA scaffold was 3.6 N/mm2.Figure 2 Immuno-staining of type II collagen in culture expanded, de
chondrocytes (A) in passage 0 attached to the surface of the cell culture fla
with strong staining of type II collagen. Further cultivation of the chondroc
stretched cells of a typical fibroblastic appearance and a gradual loss of typThe mechanical strength decreased continuously and sig-
nificantly upon prolonged incubation of the scaffold
in an aqueous solution. At day 10, the degrading
scaffold showed a median tensile strength of 1.7 N/mm2.differentiating ovine articular chondrocytes. Freshly isolated
sk and show round-shaped as well as already stretch chondrocytes
ytes up to passage 1 (B), passage 3 (C) and passage 5 (D) revealed
e II collagen.
Figure 3 Electron microscopical and biomechanical characterization of the resorbable, textile polyglycolic acid (PGA) scaffolds.
Scanning electron microscopy shows that non-woven, bulked textile structure of the PGA scaffolds with smooth and regular PGA fibers (A). PGA
fibers cut with a scalpel show a diameter of approximately 17 μm (B). Tensile strength of PGA scaffolds and degradation kinetics in phosphate
buffered saline (C). Strength is presented as median with the ends of the boxes defining the 25th and 75th percentiles and error bars defining
the 10th and 90th percentiles (* p<0.0001 versus day 2–10; + p<0.008 versus day 6–10; # p<0.002 versus day 8–10; ° p<0.003 versus day 10).
Graphical depiction of the measured forces during compression test performed with native articular cartilage as reference tissue and PGA (D) as
well as PGA-fibrin (E) scaffolds. Compression tests and stiffness of human articular cartilage (F), PGA scaffolds (G) and PGA-fibrin scaffolds (H).
Endres et al. Journal of Orthopaedic Surgery and Research 2012, 7:37 Page 6 of 14
http://www.josr-online.com/content/7/1/37Compression tests of pure PGA scaffolds (Figure 3D) and
PGA-fibrin scaffolds (Figure 3E) started at 0 N/mm2 and
showed the compression of the specimens up to a global
strain of 1/3 of the scaffolds thickness representing
the compression peak. At this point, the stress was
determined as measured force per loaded area of the
specimen. The strength in all scaffolds was higher thanin the cartilage sample. PGA-fibrin scaffolds developed
the highest stress peaks and consequently the highest
strengths. During the constant compression state a relax-
ation occurred, which was much more pronounced
in the case of PGA-fibrin scaffolds than in the tests
with pure PGA scaffolds. Consequently, PGA-fibrin scaf-
folds appeared more capable to dampen stress peaks.
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cartilage of 0.03 - 0.11 N/mm2 (Figure 3F). PGA scaffolds
showed a stiffness of 0.13 – 0.16 N/mm2 (Figure 3G), while
the stiffness of PGA-fibrin scaffolds was 0.29 – 0.44 N/
mm2 (Figure 3H).Re-differentiation of ovine chondrocytes in polyglycolic
acid-fibrin scaffolds
To assess the re-differentiation capacity of extensively
expanded ovine chondrocytes, cells cultured up to pas-
sage 3 or passage 5 (Figure 4) and were embedded in
PGA-fibrin scaffolds, grown in three-dimensional tissue
culture and evaluated histologically for the presence of
cartilage matrix molecules. Although the scaffolds grad-
ually degrade during in vitro tissue culture, the cartilage
grafts derived from 5th passage cells were cultured for
3 weeks without losing their shape and still showed
viable and evenly distributed chondrocytes (Figure 4A-C).
At day 7 (Figure 4A), the scaffold fibers appeared trans-
parent. With gradual degradation of the scaffold, the
fibers took on the red color from PI staining at day 14
(Figure 4B) and day 21 (Figure 4C). Histological staining
with alcian blue showed that the scaffold fibers remained
colorless, not taking on the alcian blue dye at day 7
(Figure 4D). At day 14, the fibers started to fragment and
were faintly stained by the alcian blue dye (Figure 4E).
After 3 weeks of cell culture, alcian blue staining showed
the fragmentation of the PGA scaffolds (Figure 4F, white
arrow) and vital chondrocytes growing adjacent to the
PGA fibers (Figure 4F, black arrow). The staining of pro-
teoglycan was weak, accumulation of proteoglycan adja-
cent to or surrounding the cells was not evident
(Figure 4F, black double arrow). Re-differentiation of
chondrocytes and formation of a cartilaginous matrix
in vitro was shown by the staining of cartilage specific type
II collagen, formed by chondrocytes expanded up to pas-
sage 3 (Figure 4G) and up to passage 5 (Figure 4H). Con-
trols gave no signal and showed the specificity of the
antibody staining (Figure 4I). A high viability of chondro-
cytes in PGA-fibrin scaffolds was evident, when 3rd pas-
sage chondrocytes were used (data not shown).Table 2 Stiffness of PGA scaffolds
No. Sample Stiffness [N/mm2]
1 human articular cartilage 1 0.1085
2 human articular cartilage 2 0.0341
3 PGA 1 0.1302
4 PGA 2 0.1499
5 PGA 3 0.1642
6 PGA-fibrin 1 0.3805
7 PGA-fibrin 2 0.4377
8 PGA-fibrin 3 0.2870Gene expression profiles of ovine chondrocytes in vitro
De- and re-differentiation of ovine chondrocytes expanded
in vitro were analyzed on the molecular level by real-time
gene expression analysis of native cartilage, expanded
chondrocytes in passage 0, passage 3, passage 5 and after
in vitro tissue culture in PGA-fibrin scaffolds for 1 week,
2 weeks and 3 weeks, using three independent and separ-
ately handled donor tissues (Figure 5). Since the re-
differentiation capacity of chondrocytes in the cartilage
grafts is of special importance for cartilage repair, statis-
tical analysis was performed, comparing the gene expres-
sion levels of the respective marker gene in propagated
chondrocytes with the levels found in three-dimensional
tissue culture in fibrin-PGA scaffolds (Table 3). The gene
expression analysis of typical cartilage marker genes type
IIα1 collagen and aggrecan showed a continuous decrease
of the expression level during expansion of cells up to pas-
sage 5. Re-differentiation of chondrocytes in PGA-fibrin
scaffolds was accompanied by a significant (p < 0.05) in-
crease of the cartilage marker gene expression levels com-
pared to the levels found in 5th passage chondrocytes. The
expression profiles of matrix modifying molecules like
matrix metalloproteinase (MMP) -1, -2, and −13 as well as
tissue inhibitors of metalloproteinases (TIMP) -1, -2, and
−3 were more heterogeneous. The expression levels of
MMP-1 and MMP-13 remained stable during the expan-
sion of cells, while the expression level of MMP-2
increased in cell culture. In the case of MMP-1 and
MMP-13, assembly of expanded chondrocytes in PGA-
fibrin scaffolds led to a significant increase of the expres-
sion levels, with a peak expression after one week in
three-dimensional tissue culture. TIMP-2 showed no dif-
ferential expression and remained stable during in vitro
culture. TIMP-1 showed a continuous expression level,
but a significant decrease after prolonged tissue culture
for three weeks compared to the gene expression level
found in expanded chondrocytes. The level of TIMP-3
decreased after the cells were transferred to the monolayer
culture (passage 0). Expansion of cells up to passage 5 was
accompanied by a continuous increase of TIMP-3 expres-
sion and a significant induction of TIMP-3 in PGA-fibrin
scaffolds compared to the expression level in culture
expanded chondrocytes. The gene expression profiles of
chondrocytes expanded up to passage 3 and passage 5
showed significant induction of chondrocyte marker genes
in three-dimensional tissue culture and revealed initiation
of chondrocyte re-differentiation in PGA-fibrin scaffolds
(Table 3).Absence of osteogenic differentiation of ovine
chondrocytes in polyglycolic acid-fibrin scaffolds
Since chondrocytes may further differentiate along the
osteogenic lineage in PGA-fibrin scaffolds, the presence
Figure 4 Histological analysis of ovine chondrocytes in three-dimensional scaffold-assisted cartilage grafts derived from 5th passage
chondrocytes. Propidiumiodide fluoresceindiacetate (PI/FDA) staining shows that the chondrocytes are evenly distributed within the PGA-fibrin
scaffold and are vital after 1 (A), 2 (B) and 3 weeks (C) of in vitro cell culture. Alcian blue staining was negative after 1 (D) and 2 (E) weeks, while
the scaffold fibers started to take on the dye after 2 weeks of cell culture (white arrowhead). After 3 weeks (F), alcian blue staining shows strong
staining of the fragmented PGA fibers (white arrowhead) and vital chondrocytes adjacent to the fibers (black arrowhead). The extracellular matrix
shows only marginal staining (black double arrowhead). Immune-staining of type II collagen – formed by chondrocytes expanded up to passage
3 (G) and up to passage 5 (H) – demonstrated the presence of this particular matrix molecule, typical for articular cartilage. Isotype controls (I)
gave no signal and show specificity of the type II collagen immune-staining.
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gene expression analysis (Figure 6). Expanded ovine
chondrocytes cultured in PGA-fibrin scaffolds for three
weeks did not form a mineralized extracellular matrix
(Figure 6A). There is a mild staining of the scaffold
fibers (Figure 6B, black double arrowheads), while chon-
drocytes showed no staining (Figure 6B, black arrow-
head). In general, the expression level of osteocalcin was
low. The mean expression level in native ovine articular
cartilage was 16% of the expression level found for the
housekeeping gene GAPDH. Expanded chondrocytes
showed levels between 0.06% and 1.9%, while chondro-
cytes embedded in PGA-fibrin scaffolds showed osteo-
calcin expression levels between 0.8% and 1.6%. There is
no evidence that ovine chondrocytes differentiate intobone or osteogenic cells, when expanded or cultured
in vitro in PGA-fibrin scaffolds.
Discussion
In the present study, we used an ovine in vitro model for
scaffold-assisted cartilage grafts and showed that exten-
sively expanded chondrocytes lose their chondrocyte
phenotype, but re-differentiate in resorbable polyglycolic
acid-fibrin polymer scaffolds in vitro as assessed by gene
expression analysis and immune-histochemical staining of
type II collagen. In addition, our data suggest that the
extracellular matrix molecules aggrecan and type II colla-
gen may be suitable markers for chondrocyte identity and
potency, regarding the use of the ovine model for pre-
clinical animal studies and quality assurance of human
Figure 5 Semi-quantitative real-time gene expression analysis of ovine chondrocytes in three-dimensional scaffold-assisted cartilage
grafts derived from 5th passage chondrocytes. Chondrocyte dedifferentiation and re-differentiation was analyzed by gene expression analysis of the
typical chondrocytic marker genes aggrecan and type IIα1 collagen. Matrix remodeling was assessed by gene expression analysis of the matrix
metalloproteinases (MMP)-1, -2 and −13 as well as the tissue inhibitors of metalloproteinases (TIMP)-1, -2 and −3. The expression level was calculated as the
percentage of the expression level of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The mean (n = 3 donors) is plotted and
the error bars represent SD. (*) significant (p<0.05) difference compared to expression level in passage 5; (+) significant (p<0.05) difference compared to
expression level in 3D grafts cultured for 1 week; (#) significant (p<0.05) difference compared to expression level in 3D grafts cultured for 2 weeks.
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spect to secure fixation of scaffold-assisted cartilage grafts
in cartilage defects, biomechanical characterization of the
scaffolds should comprise testing of tensile strengths.
A variety of studies have documented that chondro-
cytes dedifferentiate during culture and expansion in
monolayer. The cells lose their typical macroscopical
and molecular phenotype which is accompanied by the
decrease of the cartilage-specific type II collagen and the
increase of fibroblast-related type I collagen [28-30].
Three-dimensional re-arrangement of cells initiates car-
tilaginous re-differentiation of the dedifferentiated chon-
drocytes, characterized by the re-expression of cartilage
marker molecules like aggrecan and type II collagen.However, the in vitro expression levels of chondrocyte
marker genes are at least a magnitude lower than found
in native articular cartilage. This may indicate that
three-dimensional assembly of expanded chondrocytes
in PGA-fibrin scaffolds activates the chondrogenic re-
differentiation process in vitro, while tissue formation
and maturation occurs after transplantation of such
grafts in vivo. This capacity of expanded chondrocytes
embedded in fibrin and resorbable polymer scaffolds
made from PGA or polylactic acid (PLGA) copolymers
to form a cartilaginous matrix and cartilage repair tissue
in vivo has been shown in various animal studies using
nude mice, rabbit and the horse model as well as in
clinical trials [22,31-34].
Table 3 Statistical analysis of gene expression profiles of 3D cartilage grafts in vitro








type 2α1 collagen P3 0.34 0.15 0.0066 0.0039 0.0547
1 week 3D (P3) 1.50 1.00 — 0.0248 0.4258
2 weeks 3D (P3) 3.42 2.23 0.0248 — 0.9102
3 weeks 3D (P3) 5.09 6.78 0.4258 0.9102 —
P5 0.07 0.06 0.0104 0.0028 0.0039
1 week 3D (P5) 0.19 0.08 — 0.0288 0.0039
2 weeks 3D (P5) 0.40 0.21 0.0288 — 0.0160
3 weeks 3D (P5) 1.48 0.84 0.0039 0.0160 —
Aggrecan P3 2.60 1.91 0.0153 0.0031 0.0547
1 week 3D (P3) 6.69 5.47 — 0.0094 0.4547
2 weeks 3D (P3) 16.91 12.05 0.0094 — 0.0039
3 weeks 3D (P3) 8.04 8.41 0.4547 0.0039 —
P5 1.05 0.32 0.0309 0.0039 0.0002
1 week 3D (P5) 2.16 1.11 — 0.0039 0.0039
2 weeks 3D (P5) 6.27 4.56 0.0039 — 0.9449
3 weeks 3D (P5) 6.41 2.29 0.0039 0.9449 —
MMP1 P3 0.34 0.12 0.0039 0.0305 0.0008
1 week 3D (P3) 3.96 4.48 — 0.0078 0.0039
2 weeks 3D (P3) 1.20 1.07 0.0078 — 0.0009
3 weeks 3D (P3) 0.13 0.16 0.0039 0.0009 —
P5 0.23 0.14 0.0039 0.0029 0.0002
1 week 3D (P5) 3.52 4.00 — 0.0039 0.0039
2 weeks 3D (P5) 0.57 0.30 0.0039 — 0.9449
3 weeks 3D (P5) 0.07 0.10 0.0039 0.9449 —
MMP2 P3 20.81 26.32 0.0030 0.0032 0.0218
1 week 3D (P3) 52.38 38.09 — 0.4360 0.0058
2 weeks 3D (P3) 57.71 37.25 0.4360 — 0.0159
3 weeks 3D (P3) 33.18 34.32 0.0058 0.0159 —
P5 14.42 10.10 0.0118 0.0232 0.0001
1 week 3D (P5) 28.02 20.84 — 0.4063 0.2593
2 weeks 3D (P5) 33.47 28.82 0.4063 — 0.8868
3 weeks 3D (P5) 34.49 12.90 0.2593 0.8868 —
MMP13 P3 1.65 1.42 0.0078 0.0276 0.0039
1 week 3D (P3) 23.86 18.88 — 0.0151 0.0039
2 weeks 3D (P3) 8.68 6.96 0.0151 — 0.2867
3 weeks 3D (P3) 4.78 4.75 0.0039 0.2867 —
P5 0.74 0.38 0.0008 0.0052 0.0557
1 week 3D (P5) 19.00 10.39 — 0.0011 0.0008
2 weeks 3D (P5) 1.87 1.08 0.0011 — 0.0020
3 weeks 3D (P5) 0.60 0.51 0.0008 0.0020 —
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TIMP1 P3 497.9 211.8 0.3558 0.7333 0.0171
1 week 3D (P3) 561.2 189.7 — 0.5256 0.0015
2 weeks 3D (P3) 512.1 258.1 0.5256 — 0.0133
3 weeks 3D (P3) 303.6 240.8 0.0015 0.0133 —
P5 615.6 334.5 0.2188 0.5559 0.0391
1 week 3D (P5) 463.3 49.7 — 0.0364 0.3946
2 weeks 3D (P5) 676.0 229.4 0.0364 — 0.0023
3 weeks 3D (P5) 422.5 121.7 0.3946 0.0023 —
TIMP2 P3 83.0 46.5 0.2066 0.3109 0.2574
1 week 3D (P3) 119.4 43.7 — 0.6909 0.0848
2 weeks 3D (P3) 109.8 48.5 0.6909 — 0.0907
3 weeks 3D (P3) 63.4 53.1 0.0848 0.0907 —
P5 97.7 35.1 0.5837 0.4985 0.9227
1 week 3D (P5) 110.2 55.4 — 0.2950 0.4336
2 weeks 3D (P5) 86.1 19.3 0.2950 — 0.3490
3 weeks 3D (P5) 96.2 26.2 0.4336 0.3490 —
TIMP3 P3 83.2 30.5 0.0003 0.0008 0.0097
1 week 3D (P3) 204.0 67.5 — 0.0061 0.0078
2 weeks 3D (P3) 156.5 46.4 0.0061 — 0.0730
3 weeks 3D (P3) 99.8 98.9 0.0078 0.0730 —
P5 120.4 35.4 0.0488 0.0195 0.0097
1 week 3D (P5) 187.2 85.9 — 0.7876 0.1902
2 weeks 3D (P5) 197.7 69.9 0.7876 — 0.0888
3 weeks 3D (P5) 282.2 167.3 0.1902 0.0888 —
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gen are characteristic for mature cartilage tissue and
the dynamics of gene regulation processes during
chondrocyte de- and re-differentiation. The synthesis
of these markers is suggested to account for pheno-
typic stability of chondrocytes [35]. Therefore, these
molecules are suggested to be suitable markers for
chondrocyte identity and potency. The use of type II
collagen for testing chondrocyte identity is in accord-
ance with the recommendations of national orthopedic
societies for quality assurance in autologous chondro-
cyte implantation [36]. However, the re-expression of
type II collagen by expanded chondrocytes in hydrogel
cultures is not predictive for effective formation of car-
tilage repair tissue in vivo, as assessed in the small
animal nude mice model [37].
Interestingly, the re-differentiation of chondrocytes in
PGA-fibrin scaffolds was accompanied by induction of
MMP-2, TIMP-1 and −3 as well as by a peak increase of
MMP-1 and MMP-13 in the early phases of 3D tissue
culture that decreased again after prolonged in vitro culti-
vation. MMP as well as their inhibitors are key enzymes
that regulate cell-extracellular matrix interaction during
development and differentiation of cartilage. MMP-13 is
known to target type II collagen and aggrecan and can beactivated by MMP-2. MMP-1 cleaves types I and III colla-
gen and induces MMP-13 in some cell types, including
osteoarthritic chondrocytes [38-40]. Particularly in OA,
MMP-13 may play an important role in cartilage homeo-
stasis and progression of cartilage breakdown [41,42].
Consequently, an imbalance between matrix degrading
enzymes and their tissue inhibitors has been suggested in
the development of the disease, as shown by mild cartil-
age degradation in TIMP-3 deficient mice [43]. MMPs,
including MMP-13, as well as further key molecules
associated with the onset and progression of OA are
expressed in chondrocyte clusters, formed during OA.
These clusters with chondrocyte proliferation may impli-
cate a repair response with cell migration and re-
population of the diseased cartilage [44]. Since MMP-13
is not present in normal mature articular cartilage but in
degenerated chondrocytes [45], the peak expression of
MMP in the early phase and the decrease in prolonged
tissue culture suggests that three-dimensional assembly of
chondrocytes may initiate chondrocyte re-differentiation
accompanied by development towards tissue remodeling
found in normal articular cartilage. However, further
studies have to elucidate the molecular interplay and the
mechanisms underlying the balance of formation and tis-
sue remodeling in articular cartilage repair.
Figure 6 Histological staining and gene expression analysis of
ovine chondrocytes for osteogenic differentiation in three-
dimensional scaffold-assisted cartilage grafts. Von Kossa staining
of mineralized osteogenic extracellular matrix was negative (A) with
mild staining of scaffolds fibers (B, black double-arrowhead) and no
staining of chondroctyes (B, black arrowhead). The gene expression
level of the osteogenic marker gene osteocalcin was low (C). The
expression level was calculated as the percentage of the expression
level of the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The mean (n = 3 donors) is plotted and the
error bars represent SD.
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cartilage grafts do not only have to ensure formation of
appropriate cartilage repair tissue but should also be easy
in handling and allow for secure fixation of the graft in the
defect. Therefore, the resorbable scaffold has to be initially
stable. As shown here, the PGA scaffold shows a high ten-
sile strength of 3.6 N/mm2 and stiffness slightly higher
than articular cartilage. The mechanical characteristics of
cell-based cartilage grafts cultured in vitro or matured
in vivo are approximately an order of magnitude lower
than native articular cartilage [46,47]. However, in clinical
practice, the primary fixation of the scaffold by gluing, car-
tilage suture or trans-osseous fixation is of importance. If
the fixation of the graft fails, the scaffolds get detached
and result in locking or catching of the knee and conse-
quently in re-operations and a poor clinical outcome
[12,48]. Since frictional forces are suggested to be the
main reason for delamination or loosening of grafts [49],
the tensile strength of the scaffolds may be more relevant
for clinical applicability than the material’s elasticity or
compressive strength. Therefore, measuring of the tensile
strength is suggested to be of special importance for qual-
ity assurance of scaffold-based cartilage grafts. Polymer-
based textile biomaterials like PGA or PLGA scaffolds as
well as collagen-based scaffolds show sufficient tensile
strength with 10 to 40 N, as shown here and in a previous
study [50], which withstand the forces that may occur dir-
ectly after implantation of the graft and during rehabilita-
tion with typical continuous passive motion (CPM)
regime [50,51]. The PGA or PLGA scaffolds ensure initial
mechanical stability for secure fixation of the grafts and
allow for an initiation of the chondrocytic re-
differentiation process in vitro, while scaffold degradation
and maturation of mechanical stable cartilaginous tissue
occurs after transplantation in vivo [30,34]. This is in ac-
cordance with the formation and ‘mechanical’ develop-
ment of cartilaginous tissue after transplantation of bovine
articular chondrocytes embedded in PLGA-fibrin scaf-
folds, in a subcutaneous mouse model. Stiffness and ten-
sile strength of the newly formed cartilage tissue increased
between 6 and 12 weeks after transplantation of the chon-
drocyte PLGA-fibrin grafts. At 12 weeks, stiffness and
strength of the generated tissue was comparable to native
septal cartilage and showed 30-50% of the stiffness and
strength found in native articular cartilage [46].
Conclusion
Our data found in the ovine model suggest that chondro-
cytes embedded in PGA-fibrin scaffolds re-differentiate
in in vitro tissue culture without further stimuli like
chondrogenic growth factors and that the cartilage
markers type II collagen and aggrecan are relevant for
testing of cell identity and potency for chondrocyte-based
medicinal products. Characterization of the biomechanical
Endres et al. Journal of Orthopaedic Surgery and Research 2012, 7:37 Page 13 of 14
http://www.josr-online.com/content/7/1/37properties of the scaffold-assisted cartilage grafts should
focus on measuring the tensile strength and, if applic-
able, the degradation kinetics of resorbable scaffolds.
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